There’s universal agreement that fraud is a bad thing, and corresponding commitment to rooting it out wherever it’s found, but when it comes to Medicare and Medicaid, the job may not be getting done.
That’s the takeaway from a recent Government Accountability Office report that said the Centers for Medicare & Medicaid Services doesn’t conduct risk assessments of the programs or maintain an overall anti-fraud strategy. Part of the problem might be budget-related, Kirk Ogrosky, a health-care attorney with Arnold & Porter Kaye Scholer LLP, told me.
The CMS routinely operates under tight budgetary constraints, Ogrosky said, with less than 2 percent of the budget allocated to administrative costs like fraud-fighting. In contrast, most private insurance companies allocate over 6 percent of their budget to administrative costs, Ogrosky said.
“It’s not surprising that CMS hasn’t been able to execute an effective and comprehensive fraud prevention plan,” given its budgetary situation, Ogrosky, a Bloomberg Law advisory board member, told me.
While the GAO report found no evidence of formal risk assessments at the CMS, the agency has taken to address program integrity risks, Louis Saccoccio, chief executive officer of the National Health Care Anti-Fraud Association, told me.
For example, the CMS in conjunction with the Health and Human Services Office of Inspector General is actively prioritizing risks that develop within the program, Saccoccio said, such as in the case of fraud that’s arisen around the pharmacy and addiction treatment space.
“What may be lacking is a more comprehensive and overall risk assessment program that anticipates the yet to develop risks, which in programs as large and complex as Medicare and Medicaid is a challenge,” Saccoccio, a Bloomberg Law advisory board member, told me.
Read my full story here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)